HK1071079A1 - Use of soluble fgl2 as an immunosuppressant - Google Patents

Use of soluble fgl2 as an immunosuppressant

Info

Publication number
HK1071079A1
HK1071079A1 HK05104187.0A HK05104187A HK1071079A1 HK 1071079 A1 HK1071079 A1 HK 1071079A1 HK 05104187 A HK05104187 A HK 05104187A HK 1071079 A1 HK1071079 A1 HK 1071079A1
Authority
HK
Hong Kong
Prior art keywords
soluble fgl2
methods
immunosuppressant
soluble
fgl2 protein
Prior art date
Application number
HK05104187.0A
Other languages
English (en)
Inventor
Gary Levy
Original Assignee
Veritas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veritas Therapeutics Inc filed Critical Veritas Therapeutics Inc
Publication of HK1071079A1 publication Critical patent/HK1071079A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
HK05104187.0A 2002-03-01 2005-05-19 Use of soluble fgl2 as an immunosuppressant HK1071079A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36105602P 2002-03-01 2002-03-01
PCT/CA2003/000273 WO2003074068A2 (en) 2002-03-01 2003-02-28 Use of soluble fgl2 as an immunosuppressant

Publications (1)

Publication Number Publication Date
HK1071079A1 true HK1071079A1 (en) 2005-07-08

Family

ID=27789065

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104187.0A HK1071079A1 (en) 2002-03-01 2005-05-19 Use of soluble fgl2 as an immunosuppressant

Country Status (8)

Country Link
US (2) US7632495B2 (xx)
EP (1) EP1482961B1 (xx)
AT (1) ATE433326T1 (xx)
AU (1) AU2003208197A1 (xx)
CA (1) CA2477312C (xx)
DE (1) DE60327925D1 (xx)
HK (1) HK1071079A1 (xx)
WO (1) WO2003074068A2 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
CA2682429A1 (en) * 2009-05-20 2010-11-20 Gary Levy An assay for measuring plasma fgl-2 and methods and uses thereof
DK2914285T3 (en) * 2012-11-01 2017-02-27 Veterinærinstituttet New fusion proteins for the treatment of allergic diseases
US9005630B2 (en) 2012-11-01 2015-04-14 Veterinaerinstituttet Fusion proteins for the treatment of allergic diseases
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
EP4126005A4 (en) * 2020-03-31 2024-08-07 Biond Biologics Ltd IMMUNOMODULATORY COMPOSITIONS AND THEIR USE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE339964T1 (de) * 1997-05-15 2006-10-15 Trillium Therapeutics Inc Verfahren um immunkoagulation zu modulieren
AU2003202388A1 (en) * 2002-02-07 2003-09-02 Trillium Therapeutics Inc. Porcine fgl2

Also Published As

Publication number Publication date
ATE433326T1 (de) 2009-06-15
DE60327925D1 (de) 2009-07-23
WO2003074068A3 (en) 2003-12-18
US20100048486A1 (en) 2010-02-25
WO2003074068A2 (en) 2003-09-12
AU2003208197A1 (en) 2003-09-16
CA2477312A1 (en) 2003-09-12
EP1482961A2 (en) 2004-12-08
EP1482961B1 (en) 2009-06-10
US20050164923A1 (en) 2005-07-28
AU2003208197A8 (en) 2003-09-16
US7632495B2 (en) 2009-12-15
CA2477312C (en) 2013-02-26

Similar Documents

Publication Publication Date Title
HK1030625A1 (en) Methods and compositions for immunomodulation
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
EA200602137A1 (ru) Гидрогелевые препараты интерферона
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
WO2001068697A3 (en) Methods and compositions for immunoregulation
IL153359A0 (en) Peptides, compositions and methods for the treatment of burkholderia cepacia
AU2003236156A1 (en) Pharmaceutical compositions used for immune disease treatment and improvement
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
WO2005009366A3 (en) Restoring vascular function
WO2004081199A3 (en) Novel compositions and methods for the treatment of immune related disease
WO2005123113A3 (en) Interferon compositions and methods of use thereof
WO2004030631A3 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.
AU8349301A (en) Dna vaccines encoding hiv accessory proteins
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2006079121A3 (en) Methods of treating disease with glycosylated interferon
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases
EP1498145A4 (en) LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
UA81613C2 (ru) Стимуляция тимозином генетической иммунизации

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130228